FRANCE - Trophos raises EUR 8.5m in series-C financing round

The financing was led by OTC Asset Management, a new investor, and was joined by CM-CIC Asset Management. Current investors, Société Générale Asset Management, Viveris Management, Turenne Capital Partners, Blue Medical and Association Française contre les Myopathies also participated.

The company specialises in the development and commercialisation of compounds to treat neurological disorders and other conditions with medical needs not currently being met. Proceeds from this latest round of funding will specifically be used to complete phase II clinical studies of TRO19622, developed for neuropathic pain and motoneuron diseases, and to accelerate the development of TRO40303 to clinical proof-of-concept for ischemia-reperfusion injury. The sales potential within the markets addressed by these programs is reportedly in excess of EUR1bn.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France